Tag: Tepmetko for NSCLC

Home / Tepmetko for NSCLC

Categories

Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer

The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenc...
tepmetko-for-nsclc

Scan the code